Tenofovir alafenamide fumarate regulatory update

The European Commission approved an MAA for Genvoya tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine from Gilead to treat HIV infection in patients ages >=12 with a body weight of >=35 kg. The single, once-daily tablet containing 10 mg TAF, 150 mg elvitegravir, 150 mg cobicistat and 200 mg emtricitabine is approved in the U.S. for the indication (see BioCentury, Nov. 23). ...